Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs ZYDUS LIFESCIENCES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS ZYDUS LIFESCIENCES NEULAND LABS/
ZYDUS LIFESCIENCES
 
P/E (TTM) x 25.4 34.2 74.2% View Chart
P/BV x 8.1 5.8 140.4% View Chart
Dividend Yield % 0.2 0.6 26.7%  

Financials

 NEULAND LABS   ZYDUS LIFESCIENCES
EQUITY SHARE DATA
    NEULAND LABS
Mar-23
ZYDUS LIFESCIENCES
Mar-23
NEULAND LABS/
ZYDUS LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs2,004495 404.9%   
Low Rs966319 302.4%   
Sales per share (Unadj.) Rs928.4170.3 545.2%  
Earnings per share (Unadj.) Rs127.419.8 644.4%  
Cash flow per share (Unadj.) Rs168.626.9 626.3%  
Dividends per share (Unadj.) Rs10.006.00 166.7%  
Avg Dividend yield %0.71.5 45.7%  
Book value per share (Unadj.) Rs774.8173.0 447.8%  
Shares outstanding (eoy) m12.831,012.20 1.3%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.62.4 66.9%   
Avg P/E ratio x11.720.6 56.6%  
P/CF ratio (eoy) x8.815.1 58.2%  
Price / Book Value ratio x1.92.4 81.4%  
Dividend payout %7.830.3 25.9%   
Avg Mkt Cap Rs m19,052412,144 4.6%   
No. of employees `000NANA-   
Total wages/salary Rs m2,01824,564 8.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m11,912172,374 6.9%  
Other income Rs m974,746 2.1%   
Total revenues Rs m12,009177,120 6.8%   
Gross profit Rs m2,71829,677 9.2%  
Depreciation Rs m5287,227 7.3%   
Interest Rs m1311,299 10.1%   
Profit before tax Rs m2,15725,897 8.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5225,878 8.9%   
Profit after tax Rs m1,63520,019 8.2%  
Gross profit margin %22.817.2 132.6%  
Effective tax rate %24.222.7 106.7%   
Net profit margin %13.711.6 118.2%  
BALANCE SHEET DATA
Current assets Rs m7,609100,082 7.6%   
Current liabilities Rs m4,39055,267 7.9%   
Net working cap to sales %27.026.0 104.0%  
Current ratio x1.71.8 95.7%  
Inventory Days Days650 12.7%  
Debtors Days Days1,10994 1,185.3%  
Net fixed assets Rs m8,189144,776 5.7%   
Share capital Rs m1291,012 12.7%   
"Free" reserves Rs m9,812174,146 5.6%   
Net worth Rs m9,941175,158 5.7%   
Long term debt Rs m7420-   
Total assets Rs m15,798244,940 6.4%  
Interest coverage x17.520.9 83.6%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.7 107.1%   
Return on assets %11.28.7 128.4%  
Return on equity %16.411.4 143.9%  
Return on capital %21.415.5 137.9%  
Exports to sales %73.539.2 187.4%   
Imports to sales %15.111.9 127.1%   
Exports (fob) Rs m8,75067,577 12.9%   
Imports (cif) Rs m1,80420,544 8.8%   
Fx inflow Rs m8,75067,577 12.9%   
Fx outflow Rs m1,80420,544 8.8%   
Net fx Rs m6,94647,033 14.8%   
CASH FLOW
From Operations Rs m2,37226,888 8.8%  
From Investments Rs m-61511,712 -5.3%  
From Financial Activity Rs m-1,358-44,004 3.1%  
Net Cashflow Rs m403-5,338 -7.6%  

Share Holding

Indian Promoters % 32.8 75.0 43.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 29.1 18.0 161.5%  
FIIs % 22.7 5.0 454.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 67.2 25.0 268.6%  
Shareholders   27,723 306,495 9.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   SUN PHARMA    DIVIS LABORATORIES    CIPLA    DR. REDDYS LAB    MANKIND PHARMA    


More on NEULAND LABS vs Cadila Healthcare

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

NEULAND LABS vs Cadila Healthcare Share Price Performance

Period NEULAND LABS Cadila Healthcare S&P BSE HEALTHCARE
1-Day -1.12% 0.57% 1.18%
1-Month -11.56% 7.77% -0.75%
1-Year 269.91% 107.52% 61.82%
3-Year CAGR 43.81% 32.30% 18.16%
5-Year CAGR 59.26% 24.52% 19.79%

* Compound Annual Growth Rate

Here are more details on the NEULAND LABS share price and the Cadila Healthcare share price.

Moving on to shareholding structures...

The promoters of NEULAND LABS hold a 32.8% stake in the company. In case of Cadila Healthcare the stake stands at 75.0%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of NEULAND LABS and the shareholding pattern of Cadila Healthcare.

Finally, a word on dividends...

In the most recent financial year, NEULAND LABS paid a dividend of Rs 10.0 per share. This amounted to a Dividend Payout ratio of 7.8%.

Cadila Healthcare paid Rs 6.0, and its dividend payout ratio stood at 30.3%.

You may visit here to review the dividend history of NEULAND LABS, and the dividend history of Cadila Healthcare.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.